Page 50 - Read Online
P. 50

Waller et al. J Transl Genet Genom 2021;5:112-23  I  http://dx.doi.org/10.20517/jtgg.2021.09                                      Page 122

               grant, P30CA42014 from the National Cancer Institute.

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Ethics committees at the University of Utah approved this research. All participants provided written
               informed consent.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.   Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36
                   cancers in 185 countries. CA Cancer J Clin 2021.
               2.   Morgan GJ, Johnson DC, Weinhold N, et al. Inherited genetic susceptibility to multiple myeloma. Leukemia 2014;28:518-24.
               3.   Grosbois B, Jego P, Attal M, et al. Familial multiple myeloma: report of fifteen families. Br J Haematol 1999;105:768-70.
               4.   Hemminki K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 2004;108:109-14.
               5.   VanValkenburg ME, Pruitt GI, Brill IK, et al. Family history of hematologic malignancies and risk of multiple myeloma: differences by
                   race and clinical features. Cancer Causes Control 2016;27:81-91.
               6.   Bourguet CC, Grufferman S, Delzell E, Delong ER, Cohen HJ. Multiple myeloma and family history of cancer a case-control study.
                   Cancer 1985;56:2133-9.
               7.   Eriksson M, Hållberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study.
                   Cancer Causes Control 1992;3:63-7.
               8.   Schinasi LH, Brown EE, Camp NJ, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the
                   International Multiple Myeloma Consortium. Br J Haematol 2016;175:87-101.
               9.   Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic
                   disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006;118:3095-8.
               10.   Kristinsson SY, Björkholm M, Goldin LR, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree
                   relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 2009;125:2147-50.
               11.   Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer
                   2006;42:1661-70.
               12.   Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer
                   2017;17:692-704.
               13.   Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat
                   Commun 2016;7:12050.
               14.   Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
                   Nat Genet 2013;45:522-5.
               15.   Went M, Sud A, Försti A, et al; PRACTICAL consortium. Identification of multiple risk loci and regulatory mechanisms influencing
                   susceptibility to multiple myeloma. Nat Commun 2018;9:3707.
               16.   Swaminathan B, Thorleifsson G, Jöud M, et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
                   Nat Commun 2015;6:7213.
               17.   Chubb D, Weinhold N, Broderick P, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.
                   Nat Genet 2013;45:1221-5.
               18.   Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet
                   2011;44:58-61.
               19.   Halvarsson BM, Wihlborg AK, Ali M, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv
                   2017;1:619-23.
               20.   Waller RG, Darlington TM, Wei X, et al. Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma
                   risk. PLoS Genet 2018;14:e1007111.
               21.   Wei X, Calvo-Vidal MN, Chen S, et al. Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to
                   Multiple Myeloma. Cancer Res 2018;78:2747-59.
               22.   Pertesi M, Vallée M, Wei X, et al. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia
   45   46   47   48   49   50   51   52   53   54   55